The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares two-year follow-up data from the ZUMA-2 trial (NCT04880434) of brexucabtagene autoleucel (brexu-cel) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Prof. Wang highlights that the responses and safety profile remain promising at the follow-up. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the ZUMA-2 clinical trial is regarding the first CAR T-cell therapy that was approved by the FDA. So in the Phase I clinical trial, ZUMA-2, we also called it brexucabtagene autoleucel, and the trademark name is Tecartus. So with this product, even after three lines, even in the worst patient population, the overall response rate was as high as 93%. The CR rate is 67%. So with a longer follow-up, the efficacy is relatively the same...
So the ZUMA-2 clinical trial is regarding the first CAR T-cell therapy that was approved by the FDA. So in the Phase I clinical trial, ZUMA-2, we also called it brexucabtagene autoleucel, and the trademark name is Tecartus. So with this product, even after three lines, even in the worst patient population, the overall response rate was as high as 93%. The CR rate is 67%. So with a longer follow-up, the efficacy is relatively the same. Some patients have prolonged durability. So did the CAR T-cell have more toxicity? Not significantly. So even with the two-year follow-up, our data continued, our efficacy and toxicity data continued to hold. And while many, many hundreds of patients have received this product, for relapsed mantle cell lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
